关键信息
-
基因名
CLN5
- 应用
-
别名
CLN5；BMPS；Bis(monoacylglycero)phosphate synthase CLN5
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O75503
-
表达区间
47-358aa
-
氨基酸序列
IPSRRHWPVPYKRFDFRPKPDPYCQAKYTFCPTGSPIPVMEGDDDIEVFRLQAPVWEFKYGDLLGHLKIMHDAIGFRSTLTGKNYTMEWYELFQLGNCTFPHLRPEMDAPFWCNQGAACFFEGIDDVHWKENGTLVQVATISGNMFNQMAKWVKQDNETGIYYETWNVKASPEKGAETWFDSYDCSKFVLRTFNKLAEFGAEFKNIETNYTRIFLYSGEPTYLGNETSVFGPTGNKTLGLAIKRFYYPFKPHLPTKEFLLSLLQIFDAVIVHKQFYLFYNFEYWFLPMKFPFIKITYEEIPLPIRNKTLSGL
-
分子量
44.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
CLN5, or ceroid-lipofuscinosis neuronal protein 5, is linked to Batten disease, a neurodegenerative disorder characterized by lysosomal dysfunction and the accumulation of lipopigments in neurons. This disorder primarily affects children, leading to severe cognitive and motor decline, and ultimately, premature death. CLN5 mutations disrupt normal cellular processes, highlighting the importance of this protein in neuronal health. Recent studies have focused on the recombinant expression of CLN5 to better understand its structure, function, and interactions within the lysosomal milieu. By generating this recombinant protein, researchers aim to investigate the underlying mechanisms of CLN5’s role in lysosomal storage pathways and its impact on neurodegeneration. The knowledge gained from such studies is crucial for developing therapeutic interventions, including gene therapy and small molecule drugs, aimed at alleviating the symptoms of Batten disease and improving patient outcomes. Moreover, understanding CLN5's function at a molecular level could provide insights not only into Batten disease but also into related neurodegenerative disorders with lysosomal dysfunction, thus broadening the implications of this research beyond a single condition.
